JG
RPRX icon

Jefferies Group’s Royalty Pharma RPRX Stock Holding History

Jefferies Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,000
Closed -$723K – 1942
2021
Q3 		$723K Buy
+20,000
New +$777K 0.01% 1105

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Jefferies Group's RPRX Position: Q3 2022 in Review

Jefferies Group increased its Royalty Pharma (RPRX) stake by 378% in Q3 2022, buying an estimated $726K and bringing the position to 21,500 shares worth $864K. The position accounts for 0.01% of the portfolio, ranked #848.

Jefferies Group first reported a position in RPRX in Q3 2020 and has held it in 4 quarters since. The position peaked at $2.49M in Q3 2020. 319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

  • Jefferies Group held 21,500 shares of Royalty Pharma worth $864K as of Q3 2022.
  • Jefferies Group bought 16,999 Royalty Pharma shares in Q3 2022, an estimated $726K.
  • Royalty Pharma made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #848 holding.
  • Jefferies Group first reported a position in Royalty Pharma in Q3 2020 and has held it in 4 quarters since.
  • Jefferies Group's Royalty Pharma position peaked at $2.49M in Q3 2020.
  • 319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.